Babak Sayad

Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?

Babak Sayad, Mahsa Sobhani, Reza Khodarahmi · Archives of Medical Research · 2020 · 79 citations · Full text

Registered/approved Clinical Trial, Covid-19 Pandemic, Antiviral Drug Development +7

Increased incidence of rhino‐orbital mucormycosis in an educational therapeutic hospital during the COVID‐19 pandemic in western Iran: An observational study

Manouchehr Avatef Fazeli, Leila Rezaei, Etrat Javadirad et al. · Mycoses · 2021 · 58 citations · Full text

The assessment of selected MiRNAs profile in HIV, HBV, HCV, HIV/HCV, HIV/HBV Co-infection and elite controllers for determination of biomarker

Sepehr Yousefpouran, Shayan Mostafaei, Pegah Vahidi Manesh et al. · Microbial Pathogenesis · 2020 · 55 citations

Diagnostic Virology, Elite Controllers, Viral Diagnostics +11

Demographics, clinical characteristics, and outcomes of 27,256 hospitalized COVID-19 patients in Kermanshah Province, Iran: a retrospective one-year cohort study

Ezat Hesni, Babak Sayad, Fatemeh Khosravi Shadmani et al. · BMC Infectious Diseases · 2022 · 35 citations · Full text

SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial

Shahin Merat, Shahin Merat, Amir‐Houshang Sharifi et al. · Clinical Infectious Diseases · 2019 · 26 citations